KMT2B

Across TCGA pan-cancer cohorts, KMT2B Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated KMT2B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher KMT2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KMT2B expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

MESO, ACC, and THCA are the cancer types where KMT2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
ACC	DFS	Median	All	0.110	0.681	<.001	26	view →
THCA	DFS	Median	All	0.049	0.828	<.001	24	view →
UCEC	DFS	Median	All	0.814	0.612	.001	20	view →
BLCA	OS	Median	All	0.090	0.688	<.001	18	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	II,III,IV	0.157	0.682	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.568	0.936	.001	6	view →
SCLC	DFS	Median	III,IV	0.968	0.338	.024	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

KMT2B–MESO (OS)

Open the MESO breakdown →